KR20190053572A - Composition for Enhancing Physical Performance and Endurance Comprising Alginic Acid - Google Patents

Abstract

The present invention relates to a composition derived from edible resources, which is safe for use without toxicity to the body, and is effective for enhancing exercise capacity and endurance. More particularly, the present invention relates to a health functional food composition containing alginic acid or alginate as an active ingredient for enhancing exercise capacity and endurance, and a pharmaceutical composition for preventing or treating muscle weakening related diseases.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for improving exercise performance and endurance comprising alginic acid as an active ingredient,

The present invention relates to a composition derived from edible resources, which is safe for use without toxicity to the body, and is effective for improving exercise capacity and endurance.

The improvement in the environment, medical care, welfare and dietary life following the entry into the advanced economic society has greatly extended the average life expectancy of humans. As age increases, muscular strength and endurance decrease gradually due to aging. As the flexibility and agility deteriorate, there is a risk of fracture. Therefore, strengthening of muscular strength and improvement of athletic performance are the main concerns. Also, due to the nature of busy modern society, the general people demand more energy and endurance in everyday life, but the amount of exercise (activity) is decreasing. In general, if you do not exercise continuously, you will lose muscle function, decrease muscle mass and muscle nerve connexion, feel fatigue easily, become lethargic, and decrease vitality of life, resulting in a sudden drop in quality of life. The decrease in muscle mass is due to the decrease in the number of myofibers and the size of the myofiber, and the loss of myofibers is known to be about 30% between 30 and 80 years of age. Decrease in muscle strength gradually decreases after the age of 20, but falls sharply as it exceeds the age of 60, which may be due to aging, but external factors such as lack of exercise, malnutrition, trauma, illness,

It is recommended that appropriate exercise regimens be followed with appropriate exercise, such as resistance exercise, to improve / maintain exercise capacity and endurance by preventing muscle strength loss. In particular, nutritional energy supplements make it possible to get the nutrients and energy needed quickly and efficiently, and as a positive factor in improving exercise performance by delaying the accumulation of fatigue and energy exhaustion during exercise.

Steroids, which are the most effective energy supplements for improving muscle strength and endurance, can exhibit the effect of significantly increasing exercise performance. However, when taken over a certain amount of time, the risk of slowing down myocardial infarction and liver function IOCs are also included on the doping list and are prohibited from taking them. Research on protein supplements that are widely used by the general public as an energy supplement has reported that protein supplementation does not actually affect muscular strength and endurance performance during exercise. Rather, excessive amino acids are oxidized or stored in the body to produce side effects such as weight gain, high levels of calcium excreted in the urine, and extreme high-protein diets may cause irreparable damage to the kidneys.

In order to solve such a problem, recently, compositions for improving exercise ability and endurance which can be safely used without adverse effects on the body derived from natural materials, especially food materials, have been developed. For example, Patent Publication No. 10-2017-0006865 discloses a composition for promoting exercise and muscle, which comprises an extract of the genus Bacillus subtilis and Bacillus subtilis as an active ingredient, and Patent No. 10-1757070 discloses a composition containing an extract of Aspergillus as an active ingredient And 10-1594349 discloses a composition for improving exercise ability, fatigue and antioxidant activity, which comprises a leaf extract of Panax ginseng plant extract.

Alginic acid is a polysaccharide that is composed of mannuronic acid and glucuronic acid. It does not function as a nutritional ingredient because it is not degraded by human digestive enzymes, but it acts as a plant fiber and can be used as a raw material for food additives, dietary fiber aids, and industrial products. It has also been used as a pharmaceutical in various activities such as an effect of suppressing an increase in blood pressure, an effect of lowering cholesterol, arranging intestinal environment, weight loss and prevention effect on arteriosclerosis. However, there has been no report that alginate can help strengthen athletic ability or endurance.

Published Japanese Patent Application No. 10-2017-0006865 Patent No. 10-1757070 Patent No. 10-1594349

It is intended to provide a health functional food composition which can be safely used as a material of food material without side effects, but also can prevent and improve the decrease of muscle strength, thereby improving exercise capacity and endurance.

It is another object of the present invention to provide a pharmaceutical composition for preventing or treating diseases associated with weakness in muscle strength.

In order to accomplish the above object, the present invention relates to a health functional food composition containing alginic acid or alginate as an active ingredient for improving exercise capacity and endurance.

The results of the Rotarod test, the Hanging wire test, the Morris submiller test, and the forced swimming test were used to evaluate the effect of alginate on muscle strength and endurance of experimental animals. And it was confirmed that the exercise ability and endurance were improved.

Polymeric alginic acid or alginic acid salt takes longer time to dissolve at room temperature than low molecular weight alginic acid or alginate salt, and its viscosity is high as concentration increases. To solve these drawbacks, the alginic acid or alginate salt contained in the composition of the present invention is more preferably a low molecular weight alginic acid or a low molecular weight alginate. In the present invention, the low molecular weight alginic acid is obtained by decomposing the polymeric alginic acid extracted from brown algae or the like by a method such as heating hydrolysis, chemical decomposition, ultrasonic degradation, radiation decomposition or enzymatic decomposition, and the low molecular weight alginate means a salt of the decomposed low molecular weight alginic acid . In the present invention, the molecular weight of the low molecular weight alginic acid or alginate may have a weight average molecular weight of 500 to 50,000 Da.

The health functional food composition may be formulated in the form of tablets, capsules, pills or liquids or may be used as additives in various foods, beverages, gums, tea, and vitamin complexes. The composition of the present invention can be safely used without toxicity and side effects as a material derived from a food material, so that it can be safely used for prolonged use even for prophylactic purposes.

Since the composition of the present invention is effective in improving exercise capacity and endurance by strengthening muscle strength, it can be usefully used as a pharmaceutical composition for preventing or treating muscle weakness-related diseases. Examples of diseases associated with muscle weakness include, but are not limited to, myopenia, muscular dystrophy, myocarditis, muscular dystrophy, myasthenia gravis, sarcopenia, Related diseases can be useful for prevention and treatment.

The composition of the present invention may be prepared by a method known in the pharmaceutical field for use as a therapeutic agent and may be prepared by mixing with a carrier or a pharmaceutically acceptable carrier, a forming agent, . The composition of the present invention can be formulated into preparations for oral or parenteral administration. The dose of the active ingredient according to the present invention can be appropriately selected depending on the degree of absorption of the active ingredient in the body, the form of the preparation, the age, sex and condition of the patient, the degree of symptoms, etc., , And may be administered in divided doses. Typical dosages are 0.001 mg / kg · day to 10 g / kg · day.

As described above, according to the composition of the present invention, alginic acid derived from a food material is used as a natural substance, and it is useful for a health functional food composition because it has no toxicity or side effects to human body, Can be used.

In addition, the composition of the present invention can be effectively used for prevention and treatment of diseases associated with muscle weakness due to the strengthening effect of muscle strength.

Figure 1 is a graph showing the weight change of experimental animals during the test period.
FIG. 2 is a graph showing the athletic performance of each experimental group in the low-speed fixed mode Rotarod test.
Figure 3 is a graph showing the athletic performance of each experimental group in the accelerated mode Rotarod test.
FIG. 4 is a graph showing the exercise capacity of each experimental group in the Hanging Wire test. FIG.
FIG. 5 is a graph showing swimming speed of each test group in the Morris Sumi test. FIG.
6 is a graph showing the maximum swimming time of each test group in the forced swimming test.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these embodiments are merely examples for explaining the content and scope of the technical idea of the present invention, and thus the technical scope of the present invention is not limited or changed. It will be apparent to those skilled in the art that various changes and modifications can be made within the scope of the technical idea of the present invention based on these examples.

[Example]

Example 1: Preparation of experimental animals and administration of alginic acid

1) Preparation of alginic acid solution

18 mg of sodium alginate (Sodim alginate, Qingdao Gather Great Ocean Algae Industry Group Co., Ltd.) was dissolved in 3 ml of 30% polyethyleneglycol (PEG) 400 and then filtered through a syringe filter to prepare an alginic acid solution (0.6%).

2) Preparation of experimental animals and alginate administration

Three-month-old C37BL / 6 mice were used as young male mice (YM) with normal exercise capacity, and aging mice (OM) Kwangju Center for Science and Technology. The test animals were fed with standard diet (crude protein 22.1% or higher, crude fat 8.0% or less, crude fiber 5.0% or less, whey protein 8.0% or less, calcium 0.6% or more, phosphorus 0.4% or more, After being purified for 1 week in laboratory environment, it was used for the experiment.

After one week of refinement, mice with good health status were selected for each experiment. To the aged mice (OE), sodium alginate solution prepared in 1) was orally administered to each mouse in a volume of 0.1 ml once a day for 3 weeks. The vehicle was orally administered to the young mouse as a positive control (YV) and to the aged mouse as a negative control (0.1 μl) for 3 weeks once a day for 3 weeks. As a vehicle, 30% PEG 400 was injected into a syringe filter A filter solution was used.

Example 2: Change in body weight during the administration of alginic acid

The body weights of all test groups were measured during the administration period, and the results are shown in Fig .

In Figure 1, a transient weight loss was observed in all test groups on the 20th day of dosing, indicating that the dietary restoration resulted in the restoration of body weight as a result of discontinuing the dietary supplement one day prior to performing the athletic performance- Show. As a result of the long-term administration of the sample, the change in the weight of the mice was not significant in all test groups as compared with that at the initiation of the test, and it was confirmed that the conditions for stable exercise were established.

Example 3: Evaluation of athletic performance by the Rotarod test

Rotarod test was performed for limb coordination function, balance sense and motor learning ability evaluation.

The equipment used for the test was a mouse rod mounted on a Rotarod from SB Technology. After 6 days of alginate administration, they were adapted for 1 hour in the laboratory to be tested. After 7 days, they were adapted to the test environment for 30 minutes or more and then pre-training was performed for 1 minute under the fixed 4 rpm condition. To equally train the mice used in the experiment, mice that were within 1 minute were placed on a reload rod and subjected to rotarod training for a total of 1 minute.

Figure 2 shows the result in the first pre-training in a low speed fixed mode rotarod. In FIG. 2, the OE group treated with alginate showed better exercise performance and endurance even in the absence of the pre-training in the rotarod group compared to the OV group as the negative control group. It is considered that this shows muscle endurance due to alginate administration and endurance due to motor learning in rotating rod.

To evaluate the effect of repeated training on exercise performance, exercise capacity was measured on the 9th day after the alginate injection on the 3rd day of pre-training and the moment of fall on the rotarod in the accelerated mode (4 → 40rpm / 5min). As a result, it was confirmed that repetitive training improved exercise capacity and endurance in all test groups (F (2.7) = 4.346, p = 0.0593). FIG. 3 is a graph showing the results as a ratio of the athletic performance to the positive control. When compared with FIG. 2, which is a pre-training result of the low speed fixation mode, the exercise capacity of the test group (OE) Respectively. On the contrary, the exercise capacity of the negative control group (OV) was lowered to 50% or less because the exercise capacity was improved by repeated training in the experimental group and the positive control group, but the exercise capacity was not more effective than the other groups in the negative control group Because. This, in turn, means that alginate can improve athletic performance in aging mice to as high as young mice. In the result of the acceleration mode of 4 ~ 40 rpm, the experimental group treated with the drug showed a 1.78-fold increase in exercise capacity compared with the negative control group (F (2.7) = 1.063, p = 0.03949).

Example 4: Evaluation of muscle strength by hanging wire test

Rotarod of Example 3 is a test method using both forelegs and hind legs, and a hanging wire test using only forelegs is performed separately to test the exercise ability and endurance by the strength of the pure forelock. All young mice were tested only in aging mice, as they were not suitable to evaluate purely forearm athletic performance by pulling the wire by the strong forelock muscles and catching the wire with the hind legs.

The mice were placed on the wire cover of the cage after 90 minutes of alginic acid administration on the day following the 1-day rest period after the 1-day rest period (i.e., the 11th day after the rotation), and then the cage cover was turned upside down and the hanging time was measured using only the forelegs. The test was carried out for a maximum of 120 seconds, and each mouse was repeated three times at intervals of 20 minutes. The ratio of the average value of the first and the longest hanging time among the three tests to the value of the negative control group in each mouse was shown in FIG.

As shown in FIG. 4, the exercise capacity and endurance of the forelimb increased about 2.75 times by alginate administration. This means that alginate can strengthen muscular weakened muscles to improve athletic ability and endurance.

Example 5: Evaluation of athletic performance by the Sumiro test

To test the overall muscle strength of the mouse required for swimming, the test was conducted with pre-training and a visible version of the platform that could be confirmed on the surface.

For testing with the Maurice Sumi, a circular pool with a non-featured inner surface was placed in a room with various external markers visible by the swimming mouse. The water temperature in the round pool was set at room temperature or 21 ° C, and the skim milk was mixed to make the surface opaque.

Pre-training was carried out on the 13th day of alginate administration. All mice were allowed to swim freely in a platform without a platform for 60 seconds, and the swimming speed of each mouse was used as an index of exercise capacity.

Pre-training The next day, the test was performed on a visible version of the maze where the only platform to escape from the water was placed in one of the four quadrants of the circular labyrinth. Specific test methods are as follows.

The platform was placed 0.5 cm above the surface of the water, one quadrant above the water, and the mouse was placed in a maze on one side of the maze to measure the time to climb to the platform. The position of the mouse to swim in the maze was different during the test. As soon as I put my mouse in the maze, I recorded it using a video tracking system. If the mouse can not find the platform for 60 seconds, the mouse is removed from the maze and placed on the platform for 3-5 seconds to artificially recognize the position of the platform. The mouse was removed from the platform and the towel was drained and placed in the home cage. After 1 minute, the next step was taken. The above steps were repeated 3 times per block (6 attempts / 2 blocks / day) and the swimming start position at the edge between each quadrant was randomized.

On the second day and the third day, the above experiment was repeated with the platform placed at the same or different position as the first day. Data were analyzed using the average swimming speed of each mouse.

Figure 5 shows the average swimming speed of each group, showing a slight improvement in swimming speed with alginate administration (F (2,7) = 10.08, p = 0.0087 / Neuman kelus test *; p <0.05 ** ; p < 0.01).

Example 6: Evaluation of endurance by forced swimming test

The forced swimming test was performed on day 22 of alginate administration by modifying the method of Jacob and Michud. Specifically, a circular water bath having a diameter of 120 cm was filled with water to a length of 30 cm, and the water temperature was maintained at 21 ± 1 ° C. The weight corresponding to 5% of the weight of each mouse was put on the tail of the mouse and placed in the water tank at the same time, and the time until swimming was measured. The cut-off time was limited to 5 minutes.

FIG. 6 is a graph showing the results. It is shown that the swimming endurance of alginate was increased about 1.47 times as compared with the negative control (F (2,6) = 0.9091, p = 0.4520).

Claims (7)

Alginic acid or alginate as an active ingredient and a health functional food composition for improving exercise capacity and endurance.
The method according to claim 1,
Wherein the alginic acid or alginate is a low molecular weight alginic acid or a low molecular weight alginate.
3. The method of claim 2,
Wherein the low molecular weight alginic acid or the low molecular weight alginate has a weight average molecular weight of 500 to 50,000 Da.
A pharmaceutical composition for preventing or treating a weakness related to muscle weakness comprising alginic acid as an active ingredient.
5. The method of claim 4,
Wherein the disease is at least one selected from the group consisting of myopenia, muscular dystrophy, myocarditis, muscular degeneration, muscular degeneration, sarcopenia, and the like.
The method according to claim 4 or 5,
Wherein the alginic acid or alginate is a low molecular weight alginic acid or a low molecular weight alginate.
The method according to claim 6,
Wherein the low molecular weight alginic acid or the low molecular weight alginate has a weight average molecular weight of 500 to 50,000 Da.

Images